300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Energy
Non Profit
SaaS
Social Impact
Google
CleanTech
Consumer
Enterprise Software
Health Care
Local
Travel
InsurTech
Platforms
Oil and Gas
Retail
Film
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Sports
Wellness
Legal
Education
Biotechnology
Automotive
eSports
Renewable Energy
Software
Facebook
Blockchain
Theatre
Beauty
Medical
Fashion
Web3
Infrastructure
Recruiting
Celebrity
Social
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Finance
Music
Art
Social Media
Franchise
Manufacturing
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
FinTech
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Sudan
Malawi
Isle of Man
Haiti
Iran
Lesotho
Madagascar
Russian Federation
Nepal
Pakistan
Turkey
Liberia
Mexico
Tajikistan
Sweden
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Morocco
Uzbekistan
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
New Zealand
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Sierra Leone
El Salvador
Senegal
Portugal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Bermuda
Azerbaijan
Ecuador
Bahamas
Bahrain
Jersey
Estonia
Bulgaria
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Reinhard Ambros, Executive Director at Novartis Venture Fund

Reinhard Ambros

Executive Director @ Novartis Venture Fund

Basel, Switzerland

Reinhard Ambros is a Series A investor at Novartis Venture Fund in Basel focused on Biotechnology and Health Care. Reinhard Ambros

Total investments:
17
Last investment:
Lead investor:
12%

Last updated:

Industries Reinhard Ambros invests in

BiotechnologyHealth CareBiopharmaTherapeuticsPharmaceutical

Stages Reinhard Ambros invests in

Series ASeries BSeries CSeries DSeries E

Countries Reinhard Ambros invests in

United StatesSwitzerland

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 4 (24%)
  • Health Care 3 (18%)
  • Biopharma 2 (12%)
  • Therapeutics 2 (12%)
  • Pharmaceutical 2 (12%)

Stage

  • Series A 3 (18%)
  • Series B 3 (18%)
  • Series C 2 (12%)
  • Series D 2 (12%)
  • Series E 2 (12%)

Country

  • United States 3 (18%)
  • Switzerland 1 (6%)

Investments

CompanyDescriptionRoundLinks
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. $15.2M / Series A / Dec 10, 2019
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. $33M / Series E / Oct 29, 2014
Rein Therapeutics is a biopharmaceutical company that is developing therapies for pulmonary and fibrotic diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis, LTI-01 for pleural effusion, and early programs for cystic fibrosis and systemic fibrosis using peptide and proenzyme approaches. $33M / Series E / Oct 29, 2014
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. $30M / Series E / Nov 18, 2013
Rein Therapeutics is a biopharmaceutical company that is developing therapies for pulmonary and fibrotic diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis, LTI-01 for pleural effusion, and early programs for cystic fibrosis and systemic fibrosis using peptide and proenzyme approaches. $30M / Series E / Nov 18, 2013
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. $12M / Series D / Jan 14, 2013
Rein Therapeutics is a biopharmaceutical company that is developing therapies for pulmonary and fibrotic diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis, LTI-01 for pleural effusion, and early programs for cystic fibrosis and systemic fibrosis using peptide and proenzyme approaches. $12M / Series D / Jan 14, 2013
FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers.FORMA’s approach to accessing such high value drug targets, many of which pose significant challenges toconventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms.FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs. Series B / Dec 17, 2009
FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers.FORMA’s approach to accessing such high value drug targets, many of which pose significant challenges toconventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms.FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs. Series B / Dec 01, 2009
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. $40M / Series D / Jun 11, 2009
See all 17 investments →

Co-Investors

Novartis Venture Fund

About Novartis Venture Fund

VC Fund · Basel, Switzerland

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management and board experience, and capital efficiency in the program. Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

Novartis Venture Fund Contacts

NameEmailPhoneSocials
Aaron Nelson
Aaron Nelson Principal & Managing Director
Lauren Silverman
Lauren Silverman Managing Director
Anja König
Anja König Global Head Novartis Venture Fund
Bart Dzikowski
Bart Dzikowski Managing Director, Head of Transactions & Legal
Florent Gros
Florent Gros Managing Director

Sign up to unlock verified contacts

Unlock Contacts

See all 11 contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Energy
Non Profit
SaaS
Social Impact
Google
CleanTech
Consumer
Enterprise Software
Health Care
Local
Travel
InsurTech
Platforms
Oil and Gas
Retail
Film
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Sports
Wellness
Legal
Education
Biotechnology
Automotive
eSports
Renewable Energy
Software
Facebook
Blockchain
Theatre
Beauty
Medical
Fashion
Web3
Infrastructure
Recruiting
Celebrity
Social
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Finance
Music
Art
Social Media
Franchise
Manufacturing
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
FinTech
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Sudan
Malawi
Isle of Man
Haiti
Iran
Lesotho
Madagascar
Russian Federation
Nepal
Pakistan
Turkey
Liberia
Mexico
Tajikistan
Sweden
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Morocco
Uzbekistan
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
New Zealand
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Sierra Leone
El Salvador
Senegal
Portugal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Bermuda
Azerbaijan
Ecuador
Bahamas
Bahrain
Jersey
Estonia
Bulgaria
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Reinhard Ambros invest in?

Reinhard Ambros invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Reinhard Ambros?

Public channels for Reinhard Ambros include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Reinhard Ambros last invest?

The most recent investment recorded for Reinhard Ambros closed in Dec 2019. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Reinhard Ambros Reinhard Ambros Find email